Tohoku University. Research Profiles

  • Top
  • Life Sciences
  • Development of anti-fibrotic therapies with a cell line from myofibroblasts of fibrotic kidneys

Development of anti-fibrotic therapies with a cell line from myofibroblasts of fibrotic kidneys



There are serious unmet medical needs in kidney diseases. Since fibrosis is a common terminal pathology of various kidney diseases and closely related to renal failure, anti-fibrotic therapies are plausible strategies for kidney diseases. Kidney fibrosis progresses with the emergence of myofibroblasts which produce extracellular matrix. We demonstrated that myofibroblasts originate from renal interstitial fibroblasts, which produce the erythroid growth factor erythropoietin, and that the transformation is reversible. To elucidate mechanisms of kidney fibrosis, we have established a cell line derived from myofibroblasts of mouse kidneys. It has been demonstrated that epigenetic interventions restore the cells (Replic cells) to their original fibroblastic features.

Targeted Application(s)/Industry

Replic cells provide useful and precise strategies to identify anti-fibrotic drugs.


Applied Oxygen Physiology Project, NICHe

SUZUKI Norio , Professor


Related Information

Renal interstitial fibroblasts coproduce erythropoietin and renin under anaemic conditions. [EBioMedicine 64: 2021; 103209] Miyauchi K, Nakai T, Saito S, Yamamoto T, Sato K, Kato K, Nezu M, Miyazaki M, Ito S, Yamamoto M, Suzuki N*.

Efficient isolation of interstitial fibroblasts directly from mouse kidneys or indirectly after ex vivo expansion. [STAR Protoc 2: 2021; 100826] Nakai T, Iwamura Y, Suzuki N*.

An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts. [Sci Rep 9: 2019; 11254] Sato K, Hirano I, Sekine H, Miyauchi K, Nakai T, Kato K, Ito S, Yamamoto M, Suzuki N*.